TWI835735B - 減少或預防第ii型糖尿病患者中心血管事件之方法 - Google Patents

減少或預防第ii型糖尿病患者中心血管事件之方法 Download PDF

Info

Publication number
TWI835735B
TWI835735B TW107119774A TW107119774A TWI835735B TW I835735 B TWI835735 B TW I835735B TW 107119774 A TW107119774 A TW 107119774A TW 107119774 A TW107119774 A TW 107119774A TW I835735 B TWI835735 B TW I835735B
Authority
TW
Taiwan
Prior art keywords
cardiovascular
disease
canagliflozin
patient
group
Prior art date
Application number
TW107119774A
Other languages
English (en)
Chinese (zh)
Other versions
TW201904584A (zh
Inventor
諾曼 羅森塔爾
道格拉斯 威斯
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW201904584A publication Critical patent/TW201904584A/zh
Application granted granted Critical
Publication of TWI835735B publication Critical patent/TWI835735B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
TW107119774A 2017-06-12 2018-06-08 減少或預防第ii型糖尿病患者中心血管事件之方法 TWI835735B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
US62/518,547 2017-06-12

Publications (2)

Publication Number Publication Date
TW201904584A TW201904584A (zh) 2019-02-01
TWI835735B true TWI835735B (zh) 2024-03-21

Family

ID=62916717

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107119774A TWI835735B (zh) 2017-06-12 2018-06-08 減少或預防第ii型糖尿病患者中心血管事件之方法

Country Status (15)

Country Link
US (2) US20180353470A1 (https=)
EP (1) EP3638250A1 (https=)
JP (2) JP2020523408A (https=)
KR (1) KR20200014406A (https=)
CN (1) CN110740735A (https=)
AU (1) AU2018283781B2 (https=)
BR (1) BR112019026120A2 (https=)
CA (1) CA3066874A1 (https=)
CO (1) CO2019013940A2 (https=)
EA (1) EA202090028A1 (https=)
IL (1) IL271100A (https=)
MX (1) MX2019014988A (https=)
TW (1) TWI835735B (https=)
UA (1) UA127987C2 (https=)
WO (1) WO2018229630A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230046951A1 (en) * 2021-08-03 2023-02-16 National Chengchi University System and method for assessing risk of type 2 mellitus diabetes complications
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
NO2385374T3 (https=) * 2010-05-05 2014-06-07
US20130052266A1 (en) * 2010-05-11 2013-02-28 Mitsubishi Tanabe Pharma Corporation TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 ROSENTHAL N ET AL, "Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, (20150825) vol. 1358, no. 1, pages 28 - 43

Also Published As

Publication number Publication date
JP2023113644A (ja) 2023-08-16
EA202090028A1 (ru) 2020-04-03
IL271100A (en) 2020-01-30
CO2019013940A2 (es) 2020-01-17
EP3638250A1 (en) 2020-04-22
CA3066874A1 (en) 2018-12-20
MX2019014988A (es) 2020-08-06
JP2020523408A (ja) 2020-08-06
BR112019026120A2 (pt) 2020-07-07
US20210000792A1 (en) 2021-01-07
US20180353470A1 (en) 2018-12-13
AU2018283781A1 (en) 2019-12-19
CN110740735A (zh) 2020-01-31
AU2018283781B2 (en) 2023-09-28
KR20200014406A (ko) 2020-02-10
UA127987C2 (uk) 2024-03-06
WO2018229630A1 (en) 2018-12-20
TW201904584A (zh) 2019-02-01

Similar Documents

Publication Publication Date Title
JP7454531B2 (ja) エンパグリフロジンを含む医薬組成物及びその使用
Li–Sheng 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension
US20250345352A1 (en) Pharmaceutical composition, methods for treating and uses thereof
US20210346418A1 (en) Pharmaceutical composition, methods for treating and uses thereof
Hunt et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation
JP6561136B2 (ja) 勃起機能不全を治療又は改善するための方法及びｓｇｌｔ２阻害薬を含む医薬組成物
Sakai et al. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction―novel prospective cohort study―
TW202108134A (zh) 利用達格列淨治療射血分率降低的心臟衰竭之方法
JP2023113644A (ja) ２型糖尿病の患者における心血管イベントの低減又は予防方法
AU2013241776B2 (en) Basal insulin therapy
JP2020523408A5 (https=)
US20190343853A1 (en) Methods of treating hypertension
HK40021204A (en) Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
Azeez Present State and Perspectives of Type 2 Diabetes Management
Ansaripour et al. Type 2 diabetes as a prominent global health issue: A narrative review
Kavanagh Antihypertensive drugs
Ruxer et al. ``White coat hypertension''in type 2 diabetic patients
Al-Harbi An open-label, uncontrolled study to evaluate the effect of verapamil on glycaemic control in type 2 diabetes mellitus patients with hypertension
Afshinnia et al. Approach to Chronic Kidney Disease in the Diabetic Patient
Bakir et al. Novel trends in monitoring and managing diabetes mellitus using electronic nose technology
Abidoye et al. Effect of salt loading and gender influences on plasma atrial natriuretic peptide levels and cardiovascular parameters in normotensive and hypertensive Nigerians
Schindler et al. Improvement of coronary vascular dysfunction in type 2 diabetic patients with euglycemic control
Hart Autonomic and circulatory function in type 1 diabetes mellitus
Boenner et al. OP1: Risk predictors of cardio-and cerebrovascular hospital mortality in diabetic patients of the Munich Registries
HK1224940A1 (en) Methods for the treatment and prevention of renal disorders and fatty liver disorders

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees